Andrew Hollman Meyer, Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 25,468 shares at $54.51 ($1.4M) on 2025-01-02, disclosed to the SEC on 2025-01-03.
Open-market sale of $1.4M JANX by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.76 | 2,922 | $157K | 11.3% |
| 2 | $53.76 | 2,922 | $157K | 11.3% |
| 3 | $54.51 | 5,768 | $314K | 22.5% |
| 4 | $54.51 | 5,768 | $314K | 22.5% |
| 5 | $55.76 | 3,444 | $192K | 13.8% |
| 6 | $55.76 | 3,444 |
| $192K |
| 13.8% |
| 7 | $56.78 | 1,000 | $57K | 4.1% |
| 8 | $57.37 | 200 | $11K | 0.8% |
| Total | $54.79 avg | 25,468 | $1.4M | 100% |
| Filing → |
| JANX | SELL | 2025-11-14 | $100K | — | Filing → |
| JANX | SELL | 2025-10-30 | $1.0M | — | Filing → |
| JANX | SELL | 2025-05-02 | $200K | — | Filing → |